Yesterday the PTAB (Patent Trial and Appeal Board) ruled on a PGR (Post Grant Review) in favor of Concert Pharmaceuticals. The petitioner Incyte Corporation, has not demonstrated beyond a preponderance of the evidence that each challenged claims is unpatentable. Incyte Corporation could appeal to the Federal Court system, but that can take several years to play out, and may come to the same conclusion that the PTAB just did.
CTP-543's patent runs to 2037, so plenty years ahead, even considering that Concert does not plan to submit a New Drug Application to the FDA until the first half of 2023, with expected approval, either end of 2023, early 2024.
CTP-543 would be addressing the unmet need of Alopecia Areata, an autoimmune disorder that causes your hair to come out, and which there is not an FDA approved oral treatment available at this time. Phase 3 clinical trial Alopecia data from Concert is expected in the coming weeks. Concert's stock had a positive reaction to this news, chart below. Thank you for reading.
No comments:
Post a Comment